自身免疫性胰腺炎两种亚型治疗的进展

周素敏; 高普均

自身免疫性胰腺炎两种亚型治疗的进展

吉林大学第一医院肝胆胰内科

详细信息

中图分类号: R576
计量
- 文章访问数: 3669
- HTML全文浏览量: 22
- PDF下载量: 796
- 被引次数: 0
出版历程
- 出版日期: 2011-11-20

Advancement in the treatment of two subtypes of autoimmune pancreatitis

摘要

摘要: 自身免疫性胰腺炎(AIP)是由自身免疫介导的、以胰腺肿大及胰管不规则狭窄为特征的慢性胰腺炎,有着独特的临床、影像学和组织病理学特点。据其特点分为两个亚型,两种亚型的治疗、预后及复发率不同。
- 胰腺炎 /
- 自身免疫疾病
Abstract: Autoimmune pancreatitis (AIP) is a form of chronic pancreatitis characterized by auto-immune mediated, pancreatic enlargement and pancreatic duct with irregular stenosis and has special clinical, image and histopathology features.According to the features, AIP is divided into two subtypes.Treatment, prognosis and relapse rate of the two subtypes are different.
- pancreatitis /
- autoimmune diseases

HTML全文

参考文献(29)

[1]Sarles H, Sarles JC, Muratore R, et al.Chronic inflammatorysclerosis of the pancreas-an autonomous pancreatic dis-ease?[J].Am J Dig Dis, 1961, 6:688-698.

[2]Yoshida K, Toki F, Takeuchi T, et al.Chronic pancreatitiscaused by an autoimmune abnormality.Proposal of the con-cept of autoimmune pancreatitis[J].Dig Dis Sci, 1995, 40 (7) :1561-1568.

[3]Shimosegawa T, Kanno A.Autoimmune pancreatitis in Ja-pan:overview and perspective[J].Gastroenterology, 2009, 44 (6) :503-517.

[4] Kim KP, Kim MH, Song MH, et al. Autoimmune chronic pancreatitis[J]. Am Gastroenterol, 2004, 99 (8) : 1605-1616.

[5]Kim MJ, Oh CR, Lee KT.Clinical characteristics of autoim-mune pancreatitis[J].Korean Gastroenterol, 2010, 56 (5) :276-284.

[6] Finkelberg DL, Sahani D, Deshpande V, et al. Autoimmune pancreatitis[J]. N Engl Med, 2006, 355 (25) : 2670-2676.

[7] Pickartz T , Mayerle J, Lerch MM. Autoimmune pancreatitis[J]. Nat Clin Pract Gastroenterol Hepatol, 2007, 4 (6) : 314-323.

[8] Gardner TB, Levy MJ, Takahashi N, et al. Misdiagnosis of autoimmune pancreatitis: a caution to clinicians[J]. Am Gastroenterol, 2009, 104 (7) : 1620-1623.

[9]Park DH, Kim MH, Chari ST.Recent advances in autoim-mune pancreatitis[J].Gut, 2009, 58 (12) :1680-1689.

[10]Ng NK, Bong JJ, Williamson RC.Lymphoplasmacytic scle-rosing pancreatitis and retroperitoneal fibrosis[J].HPBSurg, 2008, 2008:719513.

[11] Vonlaufen A, Frossard JL. Autoimmune pancreatitis[J]. Rev Med Suisse, 2010, 6 (261) : 1662-1666.

[12]Kamisawa T, Funata N, Hayashi Y.Lymphoplasmacytic scle-rosing pancreatitis is a pancreatic lesion of IgG4-related sys-temic disease[J].Am Surg Pathol, 2004, 28 (8) :1114.

[13] Chari ST, Murray JA. Autoimmune pancreatitis, part II: the relapse[J]. Gastroenterology, 2008, 134 (2) : 625-628.

[14] Notohara K, Burgart LJ, Yadav D, et al. Idiopathic chronic pancreatitis with periductal lymphoplasmacytic infiltration: clinicopathologic features of 35 cases[J]. Am Surg Pathol, 2003, 27 (8) : 1119-1127.

[15]Zamboni G, Luttges J, Capelli P, et al.Histopathological fea-tures of diagnostic and clinical relevance in autoimmune pancre-atitis:a study on 53 resection specimens and biopsy specimens[J].Virchows Arch, 2004, 445 (6) :552-563.

[16] Sugumar A, Kloppel G, Chari ST. Autoimmune pancreatitis: pathologic subtypes and their implications for Its diagnosis[J]. AM Gastroenterology, 2009, 104 (9) : 2308-2310.

[17] Kamisawa T, Shimosegawa T, Okazaki K, et al. Standard steroid therapy for autoimmune pancreatitis[J]. Gut, 2009, 58 (11) : 1504-1507.

[18] Kamisawa T, Okamoto A, Wakabayashi T, et al. Appropriate steroid therapy for autoimmune pancreatitis based on long term outcome[J]. Scand Gastroenterol, 2008, 43 (5) : 609-613.

[19] Nishino T, Toki F, Oyama H, et al. Long term outcome of autoimmune pancreatitis after oral prednisolone therapy[J]. Intern Med, 2006, 45 (8) : 497-501.

[20] Wakabayashi T, Kawaura Y, Satomura Y, et al. Long term prognosis of duct narrowing chronic pancreatitis: Strategy for steroid treatment[J]. Pancreas, 2005, 30 (1) : 31-39.

[21]Church NI, Pereira SP, Deheragoda MG, et al.Autoimmunepancreatitis:clinical and radiological features and objectiveresponse to steroid therapy in a UK series[J].Am Gastroen-terol, 2007, 102 (11) :2417-2425.

[22] Kubota K, Iida H, Fujisawa T, et al. Clinical factors predictive of spontaneous remission or relapse in cases of autoimmune pancreatitis[J]. Gastrointest Endosc, 2007, 66 (6) : 1142-1151.

[23]Ryu JK, Chung JB, Park SW, et al.Review of 67 patientswith autoimmune pancreatitis in Korea-a multicenter nation-wide study[J].Pancreas, 2008, 37 (4) :377-385.

[24]Frulloni L, Scattolini C, Falconi M, et al.Autoimmune pan-creatitis:differences between the focal and diffuse forms in87 patients[J].Am Gastroenterol, 2009, 104 (9) :2288-2294.

[25]Kamisawa T, Okamoto A.Prognosis of autoimmune pancre-atitis[J].Gastroenterol, 2007, 42 (18) :59-62.

[26]Raina A, Yadav D, Krasinskas AM, et al.Evaluation and man-agement of autoimmune pancreatitis:experience at a large UScenter[J].Am Gastroenterol, 2009, 104 (9) :2295-2306.

[27]Sandanayake NS, Church NI, Chapman MH, et al.Presen-tation and management of post-treatment relapse in autoimmune pancreatitis/immunoglobulin G4-associated cholan-gitis[J].Clin Gastroenterol Hepatol, 2009, 7 (10) :1089-1096.

[28] Pannala R, Chari ST. Corticosteroid treatment for autoimmune pancreatitis[J]. Gut, 2009, 58 (11) : 1438-1439.

[29]Sah RP, Chari ST, Pannala R, et al.Differences in clinical pro-file and relapse rate of type 1 versus type 2 autoimmune pancre-atitis[J].Gastroenterology, 2010, 139 (1) :140-148.

施引文献

资源附件(0)

访问统计